Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, B.
Right arrow Articles by Bear, H. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, B.
Right arrow Articles by Bear, H. D.

Journal of Clinical Oncology, Vol 16, 2672-2685, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, ER Fisher, DL Wickerham, M Begovic, A DeCillis, A Robidoux, RG Margolese, AB Cruz Jr, JL Hoehn, AW Lees, NV Dimitrov and HD Bear
National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA. bfisher@aherf.edu

PURPOSE: To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between outcome and tumor response to preoperative chemotherapy, and if such therapy results in the performance of more lumpectomies. PATIENTS AND METHODS: Women (1,523) enrolled onto National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18 were randomly assigned to preoperative or postoperative AC therapy. Clinical tumor response to preoperative therapy was graded as complete (cCR), partial (cPR), or no response (cNR). Tumors with a cCR were further categorized as either pathologic complete response (pCR) or invasive cells (pINV). Disease-free survival (DFS), distant disease-free survival (DDFS), and survival were estimated through 5 years and compared between treatment groups. In the preoperative arm, proportional-hazards models were used to investigate the relationship between outcome and tumor response. RESULTS: There was no significant difference in DFS, DDFS, or survival (P = .99, .70, and .83, respectively) among patients in either group. More patients treated preoperatively than postoperatively underwent lumpectomy and radiation therapy (67.8% v 59.8%, respectively). Rates of ipsilateral breast tumor recurrence (IBTR) after lumpectomy were similar in both groups (7.9% and 5.8%, respectively; P = .23). Outcome was better in women whose tumors showed a pCR than in those with a pINV, cPR, or cNR (relapse-free survival [RFS] rates, 85.7%, 76.9%, 68.1%, and 63.9%, respectively; P < .0001), even when baseline prognostic variables were controlled. When prognostic models were compared for each treatment group, the preoperative model, which included breast tumor response as a variable, discriminated outcome among patients to about the same degree as the postoperative model. CONCLUSION: Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used to study breast cancer biology. Tumor response to preoperative chemotherapy correlates with outcome and could be a surrogate for evaluating the effect of chemotherapy on micrometastases; however, knowledge of such a response provided little prognostic information beyond that which resulted from postoperative therapy.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
H. Fiegl, A. Jones, C. Hauser-Kronberger, G. Hutarew, R. Reitsamer, R. L. Jones, M. Dowsett, E. Mueller-Holzner, G. Windbichler, G. Daxenbichler, et al.
Methylated NEUROD1 Promoter is a Marker for Chemosensitivity in Breast Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3494 - 3502.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. P. Mamounas
Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings
Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Gralow, J. A. Zujewski, and E. Winer
Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions
J. Clin. Oncol., February 10, 2008; 26(5): 696 - 697.
[Full Text] [PDF]

Home page
 JCOHome page
P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, R. G. Margolese, J. L. Hoehn, V. G. Vogel, S. R. Dakhil, et al.
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
J. Clin. Oncol., February 10, 2008; 26(5): 778 - 785.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff
Locally Advanced and Inflammatory Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790.
[Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff, D. Berry, L. A. Carey, M. Colleoni, M. Dowsett, M. Ellis, J. E. Garber, D. Mankoff, S. Paik, L. Pusztai, et al.
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 806 - 813.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt
Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy
J. Clin. Oncol., January 10, 2008; 26(2): 246 - 252.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Dawood, K. Broglio, S.-W. Kau, R. Islam, W. F. Symmans, T. A. Buchholz, S. E. McGuire, F. Meric-Bernstam, M. Cristofanilli, G. N. Hortobagyi, et al.
Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response
Oncologist, January 1, 2008; 13(1): 6 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. A. Newman, M. S. Sabel, A. V. Nees, A. Schott, K. M. Diehl, V. M. Cimmino, A. E. Chang, C. Kleer, D. F. Hayes, and L. A. Newman
Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation
Ann. Surg. Oncol., October 1, 2007; 14(10): 2946 - 2952.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al.
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
J. Clin. Oncol., October 1, 2007; 25(28): 4414 - 4422.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al.
Trends for Inflammatory Breast Cancer: Is Survival Improving?
Oncologist, August 1, 2007; 12(8): 904 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Peintinger, K. Anderson, C. Mazouni, H. M. Kuerer, C. Hatzis, F. Lin, G. N. Hortobagyi, W. F. Symmans, and L. Pusztai
Thirty-Gene Pharmacogenomic Test Correlates with Residual Cancer Burden after Preoperative Chemotherapy for Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4078 - 4082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Mazouni, F. Peintinger, S. Wan-Kau, F. Andre, A. M. Gonzalez-Angulo, W. F. Symmans, F. Meric-Bernstam, V. Valero, G. N. Hortobagyi, and L. Pusztai
Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
J. Clin. Oncol., July 1, 2007; 25(19): 2650 - 2655.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al.
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al.
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer
Ann. Onc., June 1, 2007; 18(6): 1015 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Mazouni, S-W Kau, D Frye, F Andre, H. Kuerer, T. Buchholz, W. Symmans, K Anderson, K. Hess, A. Gonzalez-Angulo, et al.
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
Ann. Onc., May 1, 2007; 18(5): 874 - 880.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. A. Carey, E. C. Dees, L. Sawyer, L. Gatti, D. T. Moore, F. Collichio, D. W. Ollila, C. I. Sartor, M. L. Graham, and C. M. Perou
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Clin. Cancer Res., April 15, 2007; 13(8): 2329 - 2334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Limentani, A. M. Brufsky, J. K. Erban, M. Jahanzeb, and D. Lewis
Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2-Overexpressing Locally Advanced Breast Cancer
J. Clin. Oncol., April 1, 2007; 25(10): 1232 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg
Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy
PNAS, March 6, 2007; 104(10): 4014 - 4019.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga
Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer?
Clin. Cancer Res., February 15, 2007; 13(4): 1071 - 1073.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara
Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer
Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
F. Peintinger, H. M. Kuerer, K. Anderson, J. C. Boughey, F. Meric-Bernstam, S. E. Singletary, K. K. Hunt, G. J. Whitman, T. Stephens, A. U. Buzdar, et al.
Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy
Ann. Surg. Oncol., November 1, 2006; 13(11): 1443 - 1449.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol., October 20, 2006; 24(30): 4888 - 4894.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. R. Hess, K. Anderson, W. F. Symmans, V. Valero, N. Ibrahim, J. A. Mejia, D. Booser, R. L. Theriault, A. U. Buzdar, P. J. Dempsey, et al.
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer
J. Clin. Oncol., September 10, 2006; 24(26): 4236 - 4244.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. G. Taghian, J.-H. Jeong, E. P. Mamounas, D. S. Parda, M. Deutsch, J. P. Costantino, and N. Wolmark
Low Locoregional Recurrence Rate Among Node-Negative Breast Cancer Patients With Tumors 5 cm or Larger Treated by Mastectomy, With or Without Adjuvant Systemic Therapy and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials
J. Clin. Oncol., August 20, 2006; 24(24): 3927 - 3932.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Tubiana-Hulin, D. Stevens, S. Lasry, J. M. Guinebretiere, L. Bouita, C. Cohen-Solal, P. Cherel, and J. Rouesse
Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution
Ann. Onc., August 1, 2006; 17(8): 1228 - 1233.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C Montagut, I Tusquets, B Ferrer, J M Corominas, B Bellosillo, C Campas, M Suarez, X Fabregat, E Campo, P Gascon, et al.
Activation of nuclear factor-{kappa} B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Endocr. Relat. Cancer, June 1, 2006; 13(2): 607 - 616.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. F. Escobar, R. J. Patrick, L. A. Rybicki, D. Hicks, D. E. Weng, and J. P. Crowe
Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 783 - 787.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Ardavanis, A. Scorilas, D. Tryfonopoulos, G. Orphanos, I. Missitzis, M. Karamouzis, M. Chrysochoou, A. Sotiropoulou, N. Arnogiannaki, G. Ioannidis, et al.
Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
Oncologist, June 1, 2006; 11(6): 563 - 573.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. M. Cohen, A. Goel, J. Phillips, R. D. Ennis, and M. L. Grossbard
The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer
Oncologist, June 1, 2006; 11(6): 630 - 640.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
N. Klauber-DeMore, D. W. Ollila, D. T. Moore, C. Livasy, B. F. Calvo, H. J. Kim, E. C. Dees, C. I. Sartor, L. R. Sawyer, M. Graham II, et al.
Size of Residual Lymph Node Metastasis After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients Is Prognostic
Ann. Surg. Oncol., May 1, 2006; 13(5): 685 - 691.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. R. Padhani, C. Hayes, L. Assersohn, T. Powles, A. Makris, J. Suckling, M. O. Leach, and J. E. Husband
Prediction of Clinicopathologic Response of Breast Cancer to Primary Chemotherapy at Contrast-enhanced MR Imaging: Initial Clinical Results
Radiology, May 1, 2006; 239(2): 361 - 374.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Thuerigen, A. Schneeweiss, G. Toedt, P. Warnat, M. Hahn, H. Kramer, B. Brors, C. Rudlowski, A. Benner, F. Schuetz, et al.
Gene Expression Signature Predicting Pathologic Complete Response With Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer
J. Clin. Oncol., April 20, 2006; 24(12): 1839 - 1845.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.-U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, et al.
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
J. Clin. Oncol., April 20, 2006; 24(12): 1940 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Guarneri, K. Broglio, S.-W. Kau, M. Cristofanilli, A. U. Buzdar, V. Valero, T. Buchholz, F. Meric, L. Middleton, G. N. Hortobagyi, et al.
Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors
J. Clin. Oncol., March 1, 2006; 24(7): 1037 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
J S Reis-Filho, C Westbury, and J-Y Pierga
The impact of expression profiling on prognostic and predictive testing in breast cancer.
J. Clin. Pathol., March 1, 2006; 59(3): 225 - 231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Tinari, R. Lattanzio, C. Natoli, E. Cianchetti, D. Angelucci, E. Ricevuto, C. Ficorella, P. Marchetti, S. Alberti, M. Piantelli, et al.
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival
Clin. Cancer Res., March 1, 2006; 12(5): 1501 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Chakravarthy, M. C. Kelley, B. McLaren, C. I. Truica, D. Billheimer, I. A. Mayer, A. M. Grau, D. H. Johnson, J. F. Simpson, R. D. Beauchamp, et al.
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
Clin. Cancer Res., March 1, 2006; 12(5): 1570 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. Tozaki, T. Kobayashi, S. Uno, K. Aiba, H. Takeyama, H. Shioya, I. Tabei, Y. Toriumi, M. Suzuki, and K. Fukuda
Breast-Conserving Surgery After Chemotherapy: Value of MDCT for Determining Tumor Distribution and Shrinkage Pattern
Am. J. Roentgenol., February 1, 2006; 186(2): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
I. Smith and S. Chua
Medical treatment of early breast cancer. I: adjuvant treatment
BMJ, January 7, 2006; 332(7532): 34 - 37.
[Full Text] [PDF]

Home page
 JCOHome page
B. T. Hennessy, G. N. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. U. Buzdar, S. W. Kau, B. Fornage, A. Sahin, K. Broglio, et al.
Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
J. Clin. Oncol., December 20, 2005; 23(36): 9304 - 9311.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Rouzier, L. Pusztai, S. Delaloge, A. M. Gonzalez-Angulo, F. Andre, K. R. Hess, A. U. Buzdar, J.-R. Garbay, M. Spielmann, M.-C. Mathieu, et al.
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
J. Clin. Oncol., November 20, 2005; 23(33): 8331 - 8339.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist, November 1, 2005; 10(10): 766 - 779.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Xu, L. Yao, T. Ouyang, J. Li, T. Wang, Z. Fan, B. Lin, Y. Lu, and Y. Xie
p53 Codon 72 Polymorphism Predicts the Pathologic Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer
Clin. Cancer Res., October 15, 2005; 11(20): 7328 - 7333.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. A. Koike Folgueira, D. M. Carraro, H. Brentani, D. F. da Costa Patrao, E. M. Barbosa, M. M. Netto, J. R. F. Caldeira, M. L. H. Katayama, F. A. Soares, C. T. Oliveira, et al.
Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer
Clin. Cancer Res., October 15, 2005; 11(20): 7434 - 7443.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, J. Wu, G. Mariani, J. Rodriguez, M. Carcangiu, D. Watson, et al.
Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women With Locally Advanced Breast Cancer
J. Clin. Oncol., October 10, 2005; 23(29): 7265 - 7277.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. M. Gonzalez-Angulo, S. E. McGuire, T. A. Buchholz, S. L. Tucker, H. M. Kuerer, R. Rouzier, S.-W. Kau, E. H. Huang, P. Morandi, A. Ocana, et al.
Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy
J. Clin. Oncol., October 1, 2005; 23(28): 7098 - 7104.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schmid, J. Krocker, C. Jehn, K. Michniewicz, S. Lehenbauer-Dehm, H. Eggemann, V. Heilmann, S. Kummel, C. O. Schulz, A. Dieing, et al.
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial
Ann. Onc., October 1, 2005; 16(10): 1624 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Katz
Does Neoadjuvant/Adjuvant Chemotherapy Change the Natural History of Classic Invasive Lobular Carcinoma?
J. Clin. Oncol., September 20, 2005; 23(27): 6796 - 6796.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, and L. A. Newman
Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy
Ann. Surg. Oncol., September 1, 2005; 12(9): 697 - 704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. C. Green, A. U. Buzdar, T. Smith, N. K. Ibrahim, V. Valero, M. F. Rosales, M. Cristofanilli, D. J. Booser, L. Pusztai, E. Rivera, et al.
Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks
J. Clin. Oncol., September 1, 2005; 23(25): 5983 - 5992.
[Abstract] [Full Text] [PDF]